



ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

September 24, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 24, 2018-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

- **2018 Cantor Global Healthcare Conference**
October 2 at 2:50pm ET
- **Leerink Partners Roundtable Series**
October 3 at 9:30am ET

A webcast of each presentation will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now." Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FR α)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180924005831/en/>

Source: ImmunoGen, Inc.

INVESTOR RELATIONS CONTACT

ImmunoGen, Inc.
Sarah Kiely, 781-895-0600
sarah.kiely@immunogen.com

or

MEDIA CONTACT

ImmunoGen, Inc.
Courtney O'Konek, 781-895-0600
courtney.okonek@immunogen.com

or

FTI Consulting
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com